Racotumomab (Vaxira) is a Cuban vaccine for advanced non-small cell lung cancer, given after first-line treatment to patients whose cancer has responded or held steady. In a placebo-controlled trial of 176 patients it lengthened median survival from 6.8 to 8.2 months. It is registered in Cuba and is not approved in the United States or the European Union.
Racotumomab is an anti-idiotype vaccine targeting the tumour-associated ganglioside NeuGcGM3, formulated with aluminium hydroxide (racotumomab-alum) and made by the Centro de Inmunología Molecular in Havana, which holds its registration. Cuba's regulator CECMED lists Vaxira under registration number B-25-015-L03, with an inscription date of 26 May 2025, for patients with advanced (stage IIIB or IV) non-small cell lung cancer who have an objective response or stable disease after first-line treatment, as switch maintenance. OnCo has not read whether there was an earlier Cuban registration, so no earlier date is given.
In a randomised, multicentre, placebo-controlled trial, 176 patients with stage IIIB or IV disease and at least stable disease after first-line chemotherapy received racotumomab-alum (87) or placebo (89). Median overall survival was 8.23 against 6.80 months (hazard ratio 0.63, 95% CI 0.46 to 0.87, P = 0.004) and median progression-free survival 5.33 against 3.90 months (hazard ratio 0.73, 95% CI 0.53 to 0.99, P = 0.039). The authors called the trial a preliminary estimate of efficacy; only five patients in each group had further anticancer treatment at progression, which is far from current practice elsewhere.
An anti-idiotype antibody that mimics NeuGcGM3, a ganglioside found on tumour cells, so that the patient's immune system makes antibodies against the ganglioside itself.
1.Racotumomab binds its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
| Where | Who pays | Help with the cost | |
|---|---|---|---|
🇨🇺 Cuba Discussed on its page | Not recorded | - | - |
Approval is the regulator's decision for any cancer indication, with the year of the first; it is not a promise that a hospital stocks the drug or that your indication is covered. Not recorded for United States, European Union, United Kingdom, Japan, China, Australia, India: a gap in our research, not a refusal. Compare products across regions.
CECMED registration B-25-015-L03 entered for switch maintenance in advanced non-small cell lung cancer (date of inscription in the summary of product characteristics); OnCo has not read whether there was an earlier Cuban registration source
| Region | Year | Indication |
|---|---|---|
| Cuba (CECMED) | 2025 | Advanced (stage IIIB or IV) non-small cell lung cancer with an objective response or stable disease after first-line treatment (switch maintenance) · Registration number B-25-015-L03, inscription date 26 May 2025; holder Centro de Inmunología Molecular. CECMED summary of product characteristics: "Para el tratamiento de pacientes portadores de carcinoma de pulmón de células no pequeñas (CPCNP), en estadíos avanzados (III b ó IV), con respuesta clínica objetiva o enfermedad estable después de tratamiento oncoespecífico de primera línea de quimioterapia-radioterapia (mantenimiento de cambio)." The year is that of the current entry; whether there was an earlier Cuban registration was not read. https://www.cecmed.cu/registro/rcp/biologicos/vaxirar-racotumomab |
| Adverse event |
|---|
| Injection-site reaction; headache, myalgia, dyspnoea, malaise, fever, chills |
From pooled data on 473 patients in five trials in the CECMED summary; the trial report names burning and pain at the injection site, bone pain and asthenia as the most common adverse events.. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Racotumomab" OR ABSTRACT:"Racotumomab" OR TITLE:"Vaxira" OR ABSTRACT:"Vaxira" OR TITLE:"Racotumomab-alum" OR ABSTRACT:"Racotumomab-alum") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Racotumomab, not a curated reading list.
Shares Center for State Control of Medicines, Equipment and Medical Devices (CECMED), CIMAB, Non-small-cell lung cancer and the tags cuba, cancer-vaccine.
Shares Center for State Control of Medicines, Equipment and Medical Devices (CECMED), Racotumomab-alum vaccine as switch maintenance in advanced non-small cell lung cancer: a randomised placebo-controlled trial.
Shares Racotumomab-alum vaccine as switch maintenance in advanced non-small cell lung cancer: a randomised placebo-controlled trial, Non-small-cell lung cancer.
Shares CIMAB, Non-small-cell lung cancer.
Shares Center for State Control of Medicines, Equipment and Medical Devices (CECMED), Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/